Alectinib controls lung cancer with epidermal growth factor receptor mutations. Ameitinib belongs to the third generation of epidermal growth factor receptor blocker, which blocks the biological effect of this target by blocking the epidermal growth factor receptor, reverses the malignant biological behavior of tumor cytology from the molecular level, and helps to inhibit the growth of the tumor or even make the tumor shrink, so Ameitinib can be used in the treatment of patients with lung cancer with epidermal growth factor receptor mutation. Ameditinib is contraindicated in patients with allergies. Taking Ameditinib may cause adverse reactions such as rash, itchy skin, nausea, vomiting, diarrhea, cardiac arrhythmia, cough, and arthralgia. It is necessary to follow the doctor’s advice to use the drug, avoid self-medication, so as not to cause the above adverse reactions. Alectinib is not the only drug for lung cancer patients, there are many other targeted drugs available, such as crizotinib and ceritinib, etc. Lung cancer patients need to go to regular medical institutions in time, complete the examination, and choose the appropriate targeted drug treatment under the guidance of doctors to avoid further progression of the disease.